Pharma73 is a Portuguese start-up, dedicated to the development, production and commercialization of a new generation of enhanced performance High Functionality Excipients (HFE’s).
Pharma73’s Shareholders are Portuguese R&D company 73100, Lda, and Venture Capital Fund FCR ACTEC II, managed by Portugal Ventures.
Pharma73’s natural biopolymer products whose unique properties enable their use as high functionality excipients in a multiplicity of pharmaceutical, food and cosmetics products, are obtained through a proprietary fermentation technology.
The company was created in October 2011, with the purpose of developing the production of new high functionality excipients from biopolymers produced by microbial fermentation developed from research and development projects developed by its R&D teams in research projects executed at the Chemistry Department of Faculdade de Ciências e Tecnologia at Universidade Nova de Lisboa (FCT/UNL), in Lisbon.
Since 2011 and up to now, Pharma73 has engaged on the Proof-of-concept stage of its biopolymer production technology platform and is planning market entry of it’s first products in 2017.